右维拉帕米作为急性髓系白血病的耐药修饰剂
Dexverapamil as resistance modifier in acute myeloid leukaemia.
作者信息
Pirker R, Zöchbauer S, Kupper H, Lassmann A, Gsur A, Frass M, Krajnik G, Knöbl P, Lechner K
机构信息
Clinic for Internal Medicine I, University of Vienna, Austria.
出版信息
J Cancer Res Clin Oncol. 1995;121 Suppl 3(Suppl 3):R21-4. doi: 10.1007/BF02351067.
In order to evaluate dexverapamil as a resistance modifier in acute myeloid leukaemia, we have added dexverapamil (4 x 300 mg/d orally) to DA chemotherapy (daunorubicin, cytosine arabinoside) in six patients with acute myeloid leukaemia. Two patients (1 first and 1 second relapse) achieved complete remission and two patients (1 refractory disease, 1 third relapse) showed some improvement. One patient in first relapse died due to disease progression and one drug-refractory patient remained refractory. The peak plasma levels of dexverapamil and nordexverapamil ranged from about 600 to 4100 ng/ml and from 450 to 1130 ng/ml, respectively. Major sideeffects were hypotension and sinus bradycardia. These results show the need for further evaluation of dexverapamil as a resistance modifier in acute myeloid leukaemia.
为了评估右维拉帕米作为急性髓性白血病耐药调节剂的效果，我们对6例急性髓性白血病患者在DA化疗（柔红霉素、阿糖胞苷）基础上加用右维拉帕米（4×300mg/d口服）。2例患者（1例首次复发、1例第二次复发）获得完全缓解，2例患者（1例难治性疾病、1例第三次复发）有一定改善。1例首次复发患者死于疾病进展，1例药物难治性患者仍为难治性。右维拉帕米和去甲右维拉帕米的血浆峰值水平分别约为600至4100 ng/ml和450至1130 ng/ml。主要副作用为低血压和窦性心动过缓。这些结果表明，需要进一步评估右维拉帕米作为急性髓性白血病耐药调节剂的作用。
Zotero 插件